Ignyta, Inc. (NASDAQ:RXDX) – Analysts at Cantor Fitzgerald issued their FY2016 earnings per share (EPS) estimates for shares of Ignyta in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein expects that the firm will post earnings per share of ($2.58) for the year. Cantor Fitzgerald also issued estimates for Ignyta’s FY2017 earnings at ($2.53) EPS.

Several other research firms also recently issued reports on RXDX. Jefferies Group restated a “buy” rating and set a $20.00 price objective on shares of Ignyta in a report on Wednesday, November 30th. Zacks Investment Research upgraded shares of Ignyta from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Friday, November 11th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Ignyta presently has an average rating of “Buy” and an average target price of $16.04.

COPYRIGHT VIOLATION WARNING: This piece of content was first published by Watch List News and is the propert of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The original version of this piece of content can be read at http://www.watchlistnews.com/cantor-fitzgerald-comments-on-ignyta-inc-s-fy2016-earnings-rxdx/1061053.html.

Shares of Ignyta (NASDAQ:RXDX) opened at 5.20 on Friday. The company’s market cap is $216.59 million. Ignyta has a 1-year low of $4.15 and a 1-year high of $11.90. The firm’s 50-day moving average is $6.02 and its 200-day moving average is $5.76.

Ignyta (NASDAQ:RXDX) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11.

A number of large investors have recently modified their holdings of the stock. Great Point Partners LLC purchased a new stake in shares of Ignyta during the third quarter worth approximately $21,859,000. Victory Capital Management Inc. purchased a new stake in shares of Ignyta during the third quarter worth approximately $14,911,000. RS Investment Management Co. LLC raised its stake in shares of Ignyta by 20.0% in the second quarter. RS Investment Management Co. LLC now owns 2,032,793 shares of the biopharmaceutical company’s stock worth $11,018,000 after buying an additional 338,794 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Ignyta by 26.9% in the second quarter. Vanguard Group Inc. now owns 955,541 shares of the biopharmaceutical company’s stock worth $5,179,000 after buying an additional 202,330 shares in the last quarter. Finally, BlackRock Fund Advisors raised its stake in shares of Ignyta by 8.9% in the third quarter. BlackRock Fund Advisors now owns 825,798 shares of the biopharmaceutical company’s stock worth $5,194,000 after buying an additional 67,330 shares in the last quarter. Hedge funds and other institutional investors own 61.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first published by Watch List News and is the propert of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The original version of this piece of content can be read at http://www.watchlistnews.com/cantor-fitzgerald-comments-on-ignyta-inc-s-fy2016-earnings-rxdx/1061053.html.

About Ignyta

Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.

5 Day Chart for NASDAQ:RXDX

Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.